EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial ( PACIFIC )

Dennis J Dlugos iD, Ingrid E Scheffer iD, Jacqueline A French iD, David G Vossler iD, Chad Orevillo iD, Shikha Polega iD, Randall Kaye iD, and the LP352‐201 Study Investigators

Epilepsia · 2026

DOI: 10.1111/epi.18689 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Epilepsia, 2026. Verfasst von Dennis J Dlugos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Seizures. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Funded by Longboard Pharmaceuticals (now a part of H. Lundbeck A/S).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).

Methods

Eligible participants had a DEE diagnosis, were aged 12–65 years, and were taking 1–4 concomitant antiseizure medications. Randomization to treatment groups (4:1 bexicaserin:placebo) was stratified by type of DEE (Dravet syndrome [DS], Lennox–Gastaut syndrome [LGS], or DEE Other). Following a 28‐day baseline period, the treatment period consisted of a 15‐day flexible uptitration period (6, 9, or 12 mg three times daily, 5 days each) and a 60‐day maintenance period on the highest tolerated dose. Primary end points were safety (adverse events) and change from baseline in countable motor seizure frequency.

Results

Forty‐three and nine participants were assigned to bexicaserin treatment and placebo, respectively, and received ≥1 dose (safety set); 35 bexicaserin and nine placebo participants completed titration, entered the maintenance period, and had ≥1 seizure measurement during the maintenance period (full analysis set). Twenty‐eight of 43 bexicaserin‐treated participants (65.1%) and three of nine (33.3%) in the placebo group reported drug‐related treatment‐emergent adverse events (TEAEs); seven of 43 participants (16.3%) discontinued bexicaserin due to a TEAE during titration and two of 43 (4.7%) during maintenance, most frequently due to somnolence. Median reductions in countable motor seizure frequencies were −59.8% with bexicaserin and −17.4% with placebo; reductions with bexicaserin were observed across DEEs (DS, −74.6%; LGS, −50.8%; DEE Other, −65.5%). The proportion of participants achieving ≥50% reductions during the treatment period (responder analysis) was 60.0% with bexicaserin versus 33.3% with placebo. Significance Bexicaserin was well tolerated and associated with clinically relevant reductions in countable motor seizure frequencies in participants with a variety of DEEs. This novel trial design may expand treatment access to patients previously excluded from clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsSeizuresHumansMaleDouble-Blind MethodAdultFemaleAdolescentChildMiddle AgedYoung AdultAgedTreatment OutcomeLennox Gastaut SyndromeDose-Response Relationship, DrugEpilepsies, Myoclonic

Stichwörter der Autor:innen

bexicaserindevelopmental and epileptic encephalopathiesseizuresserotonin

Substanzen

Anticonvulsants

Autor:innen und Institutionen

  • Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Epilepsy Research Centre, University of Melbourne, Austin Health, Heidelberg, Victoria, Australia.
  • Department of Paediatrics, Royal Children's Hospital, University of Melbourne, Parkville, Victoria, Australia.
  • Florey Institute of Neuroscience and Mental Health and Murdoch Children's Research Institute, Parkville, Victoria, Australia.
  • New York University Grossman School of Medicine, New York, New York, USA.
  • University of Washington School of Medicine, Seattle, Washington, USA.

ORCID-Profile: Dennis J Dlugos, Ingrid E Scheffer, Jacqueline A French, David G Vossler, Chad Orevillo, Shikha Polega, Randall Kaye

Förderung

  • Funded by Longboard Pharmaceuticals (now a part of H. Lundbeck A/S)

Zitieren

APA

Dlugos, D. J., Scheffer, I. E., French, J. A., Vossler, D. G., Orevillo, C., Polega, S., Kaye, R., & and the LP352‐201 Study Investigators (2026). Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial ( PACIFIC ). Epilepsia. https://doi.org/10.1111/epi.18689

Vancouver

Dlugos DJ, Scheffer IE, French JA, Vossler DG, Orevillo C, Polega S, et al. Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial ( PACIFIC ). Epilepsia. 2026. doi:10.1111/epi.18689

BibTeX
@article{Dlugos2026,
  author = {Dlugos, Dennis J and Scheffer, Ingrid E and French, Jacqueline A and Vossler, David G and Orevillo, Chad and Polega, Shikha and Kaye, Randall and and the LP352‐201 Study Investigators, and the LP352‐201 Study Investigators},
  title = {Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial ( PACIFIC )},
  journal = {Epilepsia},
  year = {2026},
  doi = {10.1111/epi.18689}
}
Kostenlos starten →